Harvard Bioscience, Inc. Aktie News

Harvard Bioscience, Inc. ( HBIO ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants John Duke - President, CEO & Director Mark Frost - Interim CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Taylor Krafchik Lucas Baranowski - KeyBanc Capital Markets Inc., Research Division Bruce Jackson - The Benchmark Company, LLC, R...

Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by Operations Company Expects to Refinance or Repay the Debt in the Fourth Quarter Fourth Quarter 2025 Guidance Reflects Increased Demand and Backlog, Improved Operations and Strong Financial Discipline HOLLISTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) ...

HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on November 6, 2025, and will hold a conference call to discuss the results at 8:00 a.m.

HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world's largest and most trusted scientific suppliers.

HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025.

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants John Duke - President, CEO & Director Mark T. Frost - Interim CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Bruce David Jackson - The Benchmark Company, LLC, Research Division Paul Richard Knight - KeyBanc Capital Mark...

Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline New Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial ...

HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the results at 8:00 a.m.